Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study

Abstract Brucellosis is regarded as one of the world’s most severe zoonotic diseases. This study aimed to investigate the possibility of using recombinant Lactococcus lactis (L. lactis) as a live vector to produce recombinant Brucella abortus (B. abortus) Omp10. The gene sequences were obtained from...

Full description

Bibliographic Details
Main Authors: Mahsa Kazemi-Roudsari, Abbas Doosti, Mohammad-Saeid Jami
Format: Article
Language:English
Published: SpringerOpen 2024-01-01
Series:AMB Express
Subjects:
Online Access:https://doi.org/10.1186/s13568-023-01638-4
_version_ 1797362864604839936
author Mahsa Kazemi-Roudsari
Abbas Doosti
Mohammad-Saeid Jami
author_facet Mahsa Kazemi-Roudsari
Abbas Doosti
Mohammad-Saeid Jami
author_sort Mahsa Kazemi-Roudsari
collection DOAJ
description Abstract Brucellosis is regarded as one of the world’s most severe zoonotic diseases. This study aimed to investigate the possibility of using recombinant Lactococcus lactis (L. lactis) as a live vector to produce recombinant Brucella abortus (B. abortus) Omp10. The gene sequences were obtained from GenBank. The proteins’ immunogenicity was assessed using Vaxijen. After confirming the cloning of the Omp10 gene in the pNZ8148 vector by enzymatic digestion and PCR, transformation into L. lactis was done. SDS-PAGE and western blot methods evaluated omp10 protein expression. Mice received oral recombinant L. lactis vaccines. IgG antibodies against Omp10 were tested using ELISA. Real-time PCR and ELISA were used to analyze cytokine responses. Survival rate and histopathological changes were evaluated after the challenge. Omp10 was chosen for its 1.5524 antigenicity score. Enzymatic digestion and PCR identified a 381-bp gene fragment. A 10 kDa band indicated the success of L. lactis transformation. Mice administered the L. lactis-pNZ8148-Omp10-Usp45 vaccination 14 days after priming showed significantly higher Omp10-specific total IgG and IgG1 (P < 0.001) than the PBS control group. The mice who received the L. lactis-pNZ8148-Omp10-Usp45 and IRBA vaccines had significantly elevated levels of IFN-γ, TNFα, IL-4, and IL-10 in samples collected on days 14 and 28 (P < 0.001). Inflammatory response, morphological damage, alveolar edema, and lymphocyte infiltration were reduced in the target group. A recombinant L. lactis expressing the Omp10 protein was constructed as an oral Lactococcus-based vaccine and compared to live attenuated vaccines for future brucellosis investigations.
first_indexed 2024-03-08T16:13:33Z
format Article
id doaj.art-a33af7467a6b440b961e33c350455f47
institution Directory Open Access Journal
issn 2191-0855
language English
last_indexed 2024-03-08T16:13:33Z
publishDate 2024-01-01
publisher SpringerOpen
record_format Article
series AMB Express
spelling doaj.art-a33af7467a6b440b961e33c350455f472024-01-07T12:48:23ZengSpringerOpenAMB Express2191-08552024-01-0114111410.1186/s13568-023-01638-4Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo studyMahsa Kazemi-Roudsari0Abbas Doosti1Mohammad-Saeid Jami2Department of Biology, Shahrekord Branch, Islamic Azad UniversityBiotechnology Research Center, Shahrekord Branch, Islamic Azad UniversityDepartment of Biology, Shahrekord Branch, Islamic Azad UniversityAbstract Brucellosis is regarded as one of the world’s most severe zoonotic diseases. This study aimed to investigate the possibility of using recombinant Lactococcus lactis (L. lactis) as a live vector to produce recombinant Brucella abortus (B. abortus) Omp10. The gene sequences were obtained from GenBank. The proteins’ immunogenicity was assessed using Vaxijen. After confirming the cloning of the Omp10 gene in the pNZ8148 vector by enzymatic digestion and PCR, transformation into L. lactis was done. SDS-PAGE and western blot methods evaluated omp10 protein expression. Mice received oral recombinant L. lactis vaccines. IgG antibodies against Omp10 were tested using ELISA. Real-time PCR and ELISA were used to analyze cytokine responses. Survival rate and histopathological changes were evaluated after the challenge. Omp10 was chosen for its 1.5524 antigenicity score. Enzymatic digestion and PCR identified a 381-bp gene fragment. A 10 kDa band indicated the success of L. lactis transformation. Mice administered the L. lactis-pNZ8148-Omp10-Usp45 vaccination 14 days after priming showed significantly higher Omp10-specific total IgG and IgG1 (P < 0.001) than the PBS control group. The mice who received the L. lactis-pNZ8148-Omp10-Usp45 and IRBA vaccines had significantly elevated levels of IFN-γ, TNFα, IL-4, and IL-10 in samples collected on days 14 and 28 (P < 0.001). Inflammatory response, morphological damage, alveolar edema, and lymphocyte infiltration were reduced in the target group. A recombinant L. lactis expressing the Omp10 protein was constructed as an oral Lactococcus-based vaccine and compared to live attenuated vaccines for future brucellosis investigations.https://doi.org/10.1186/s13568-023-01638-4BrucellosisLactococcus lactisOmp10Oral vaccine
spellingShingle Mahsa Kazemi-Roudsari
Abbas Doosti
Mohammad-Saeid Jami
Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
AMB Express
Brucellosis
Lactococcus lactis
Omp10
Oral vaccine
title Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
title_full Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
title_fullStr Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
title_full_unstemmed Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
title_short Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study
title_sort design of an oral vaccine using lactococcus lactis against brucellosis an in vitro and in vivo study
topic Brucellosis
Lactococcus lactis
Omp10
Oral vaccine
url https://doi.org/10.1186/s13568-023-01638-4
work_keys_str_mv AT mahsakazemiroudsari designofanoralvaccineusinglactococcuslactisagainstbrucellosisaninvitroandinvivostudy
AT abbasdoosti designofanoralvaccineusinglactococcuslactisagainstbrucellosisaninvitroandinvivostudy
AT mohammadsaeidjami designofanoralvaccineusinglactococcuslactisagainstbrucellosisaninvitroandinvivostudy